CIK 0001503802 · Non-accelerated filer<br>Smaller reporting company
Karyopharm Therapeutics Inc.
Sign in to watch- Tickers
- KPTI KPTIQ
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 263931704
- Phone
- 617-658-0600
- Business address
- 85 WELLS AVENUE, SECOND FLOOR, NEWTON, MA, 02459
Securities
- KPTI Common stock Nasdaq
- KPTIQ Common stock
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $2,135
- in 3 filings
Net −$2,135. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-28 | Cheng Sohanya Roshan EVP & Chief Commercial Officer | Grant or award · Stock Option (right to buy) | +10,833 | 10,833 | ||
| 2025-02-28 | Cheng Sohanya Roshan EVP & Chief Commercial Officer | Grant or award · Stock Option (right to buy) | +9,166 | 9,166 | ||
| 2025-02-28 | Rangwala Reshma EVP & Chief Medical Officer | Grant or award | +5,416 | 28,276 | ||
| 2025-02-28 | Rangwala Reshma EVP & Chief Medical Officer | Grant or award | +4,583 | 32,859 | ||
| 2025-02-28 | Rangwala Reshma EVP & Chief Medical Officer | Grant or award · Stock Option (right to buy) | +10,833 | 10,833 | ||
| 2025-02-28 | Rangwala Reshma EVP & Chief Medical Officer | Grant or award · Stock Option (right to buy) | +9,166 | 9,166 | ||
| 2025-02-28 | Poulton Stuart EVP, Chief Development Officer | Grant or award | +5,000 | 26,379 | ||
| 2025-02-28 | Poulton Stuart EVP, Chief Development Officer | Grant or award | +4,583 | 30,962 | ||
| 2025-02-28 | Poulton Stuart EVP, Chief Development Officer | Grant or award · Stock Option (right to buy) | +10,000 | 10,000 | ||
| 2025-02-28 | Poulton Stuart EVP, Chief Development Officer | Grant or award · Stock Option (right to buy) | +9,166 | 9,166 | ||
| 2025-02-28 | Abate Kristin Chief Accounting Officer | Grant or award | +933 | 10,284 | ||
| 2025-02-28 | Abate Kristin Chief Accounting Officer | Grant or award · Stock Option (right to buy) | +1,866 | 1,866 | ||
| 2025-02-28 | Paulson Richard A. President and CEO | Grant or award | +20,000 | 94,678 | ||
| 2025-02-28 | Paulson Richard A. President and CEO | Grant or award · Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2025-02-28 | Mano Michael SVP, General Counsel&Secretary | Grant or award | +3,333 | 21,590 | ||
| 2025-02-28 | Mano Michael SVP, General Counsel&Secretary | Grant or award | +2,250 | 23,840 | ||
| 2025-02-28 | Mano Michael SVP, General Counsel&Secretary | Grant or award · Stock Option (right to buy) | +6,666 | 6,666 | ||
| 2025-02-28 | Mano Michael SVP, General Counsel&Secretary | Grant or award · Stock Option (right to buy) | +4,500 | 4,500 | ||
| 2025-02-18 | Poulton Stuart EVP, Chief Development Officer | Sale | −5,914 | $0.63 | $4K | 320,714 |
| 2025-02-04 | Paulson Richard A. President and CEO | Sale | −4,099 | $0.65 | $3K | 1,120,158 |
Page 5 of 7 · 138 trades